Eliem Therapeutics Announces Officer Departure, Equity Sales

Ticker: CLYM · Form: 8-K · Filed: Apr 11, 2024 · CIK: 1768446

Eliem Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyEliem Therapeutics, INC. (CLYM)
Form Type8-K
Filed DateApr 11, 2024
Risk Levelmedium
Pages14
Reading Time17 min
Key Dollar Amounts$0.0001, $1,000,000, $500,000, $3.84, $120.0 m
Sentimentneutral

Sentiment: neutral

Topics: officer-departure, equity-sale, material-agreement

TL;DR

Eliem Therapeutics CMO out, unregistered equity sold.

AI Summary

Eliem Therapeutics, Inc. announced on April 10, 2024, the departure of Dr. Andrew Reisner from his role as Chief Medical Officer. The company also disclosed information regarding unregistered sales of equity securities and entered into a material definitive agreement. The filing also includes details on compensatory arrangements for certain officers and Regulation FD disclosures.

Why It Matters

The departure of a key officer like the CMO can signal internal changes or strategic shifts within the company, while equity sales might indicate financing activities or insider transactions.

Risk Assessment

Risk Level: medium — The departure of a key executive and unregistered equity sales can introduce uncertainty and potential volatility for investors.

Key Players & Entities

FAQ

Who has departed from Eliem Therapeutics, Inc. and in what capacity?

Dr. Andrew Reisner has departed from his role as Chief Medical Officer.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is April 10, 2024.

What types of transactions are disclosed in this filing besides the officer departure?

The filing discloses entry into a material definitive agreement, unregistered sales of equity securities, and compensatory arrangements of certain officers.

What is the exact name of the company filing this report?

The exact name of the registrant is Eliem Therapeutics, Inc.

What is the state of incorporation for Eliem Therapeutics, Inc.?

Eliem Therapeutics, Inc. is incorporated in Delaware.

Filing Stats: 4,348 words · 17 min read · ~14 pages · Grade level 17.5 · Accepted 2024-04-11 08:01:06

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for the Company, Tenet and the combined company following the anticipated consummation of the proposed Acquisition; the anticipated size of and investors in the proposed Private Placement; the anticipated benefits of the Acquisition; the anticipated timing of the closing the Acquisition and the Private Placement, the strategy, the anticipated milestones and key inflection points of the combined company; the anticipated use of proceeds of the Private Placement, the expected cash and cash equivalents of the combined company at closing of the Acquisition and the Private Placement and the anticipated cash runway of the combined company; the expected ownership, management team and board of directors of the combined company; Tenet's TNT119 product candidate, including expectations regarding TNT119's therapeutic benefits, clinical potential and clinical development, and anticipated timelines for initiating clinical trials of TNT119, including initiating Phase 2 clinical trials for the treatment of systemic lupus erythematosus and immune thrombocytopenia in the second half of 2024; and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," "will," "working" and similar expressions. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. The combined company may not actually achieve the plans, intentions or expectations disclosed in these forward

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 2.1* Agreement and Plan of Merger and Reorganization, dated as of April 10, 2024, by and among Eliem Therapeutics, Inc., Tango Merger Sub, Inc., Tenet Medicines, Inc. and, solely in his capacity as the Company Equityholder Representative, Stephen Thomas 10.1 Form of Company Support Agreement 10.2 Form of Tenet Support and Joinder Agreement 10.3 Form of Lock-Up Agreement 10.4 Securities Purchase Agreement, dated April 10, 2024, by and among Eliem Therapeutics, Inc. and the persons party thereto 10.5 Registration Rights Agreement, dated April 10, 2024, by and among Eliem Therapeutics, Inc. and the persons party thereto 99.1 Joint Press Release issued on April 11, 2024 99.2 Investor Presentation, dated April 11, 2024 99.3 Transcript of webcast, dated April 11, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL) * Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any exhibits or schedules so furnished.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ELIEM THERAPEUTICS, INC. Date: April 11, 2024 By: /s/ Andrew Levin Name: Andrew Levin, M.D., Ph.D. Title: Executive Chairman of the Board of Directors

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing